Despite the potential therapeutic benefits, targeting NBS1 poses several challenges. One major concern is achieving specificity, as inhibition of NBS1 in normal cells could lead to severe toxicity due to impaired DNA repair. Additionally, the redundancy and complexity of DNA repair pathways can allow cancer cells to compensate for the loss of NBS1 function, reducing the effectiveness of targeted therapies. Thus, a deeper understanding of NBS1's interactions and functions is necessary to overcome these challenges.
